VRX - Valeant Pharmaceuticals International, Inc.

NYSE - NYSE Delayed Price. Currency in USD
22.24
+0.02 (+0.09%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close22.22
Open22.16
Bid0.00 x 4000
Ask22.25 x 4000
Day's Range22.09 - 22.32
52 Week Range10.94 - 24.43
Volume3,470,573
Avg. Volume9,643,567
Market Cap7.768B
Beta-0.94
PE Ratio (TTM)3.26
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Tesla is near the top of list of stocks that Wall Street is most confused about
    CNBCyesterday

    Tesla is near the top of list of stocks that Wall Street is most confused about

    Analysts at the nation's top brokerages are divided on the trajectory of electric car maker Tesla. And it's starting to show.

  • Financial Times4 days ago

    [$$] A closer look at the great Maryland pension fees debate

    Everyone knows that Maryland does two things: crab cakes and football. The think-tank last month accused the state's pension scheme of paying an estimated $172m in undisclosed performance fees to all of its alternative investment managers, including private equity, hedge fund and commodity managers, in the year to June 30, 2017.

  • Former CEO of Hatboro mail-order pharmacy convicted of fraud, money laundering charges
    American City Business Journals4 days ago

    Former CEO of Hatboro mail-order pharmacy convicted of fraud, money laundering charges

    The former Philidor CEO was accused of personally receiving more than $40 million from Valeant when it bought the mail-order pharmacy, then secretly kicked back $9.7 million to a Valeant manager.

  • Ex-Valeant, Philidor executives convicted of kickback scheme
    Reuters4 days ago

    Ex-Valeant, Philidor executives convicted of kickback scheme

    A former Valeant Pharmaceuticals International Inc (VRX.TO) executive and the former chief of mail order pharmacy Philidor Rx Services were found guilty on Tuesday of defrauding Valeant through a multimillion-dollar kickback scheme. The verdict, handed up by a jury in Manhattan federal court, comes on the heels of Valeant's announcement that it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals under its previous management. Gary Tanner, a former senior director at Valeant, and Andrew Davenport, the former head of the now-defunct Philidor, were convicted of fraud and conspiracy.

  • Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribe
    Fortune4 days ago

    Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribe

    Gary Tanner was found guilty of accepting a $10 million bribe.

  • The Wall Street Journal4 days ago

    Jury Finds Former Valeant Exec Guilty on Charges Related to Kickback Scheme

    A Manhattan federal jury found a former executive at Valeant Pharmaceuticals International Inc. guilty of charges that he defrauded the pharmaceutical giant through a multimillion-dollar kickback scheme. The former Valeant executive, Gary Tanner, and his co-defendant, Andrew Davenport—the former chief executive of Philidor Rx Services, a specialty mail-order pharmacy involved in the scheme—were both convicted Tuesday on all four criminal counts they faced, including honest services wire fraud and money-laundering conspiracy. A lawyer for Mr. Davenport didn’t immediately respond to a request for comment.

  • Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribe
    Bloomberg4 days ago

    Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribe

    A former Valeant Pharmaceuticals International Inc. executive was found guilty of accepting a $10 million bribe for manipulating the company’s takeover of a startup mail-order pharmacy in 2014 -- the latest fallout from a scandal that shook the drugmaker. Former Philidor Rx Services LLC Chief Executive Officer Andrew Davenport, who paid the kickback, was also convicted on Tuesday after a three-week trial. Federal prosecutors accused Tanner of taking the bribe after Valeant agreed in December 2014 to pay more than $100 million for the option to buy Philidor in 10 years.

  • Financial Times5 days ago

    [$$] Leveraged loan rush sees borrowers gain balance of power

    was under investigation by the US Securities and Exchange Commission and investors were questioning its opaque accounting. Now, the company, which in July will rebrand itself as Bausch Health, is firmly in control of the refinancing of a loan. The reversal in the balance of power between the drugmaker and investors is a striking example of white-hot demand for leveraged loans, or those made to speculative grade-rated borrowers.

  • Benzinga7 days ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • InvestorPlace9 days ago

    Ackman Has a Point About United Technologies Corporation Stock

    Activist investor Bill Ackman is calling for another company breakup as a means of “unlocking value.” The target this time? Owners of UTX stock have a right to be worried, not so much because Ackman is wrong (he may well be right), but because the activist investor and hedge fund manager can cause more than a little chaos when he gets involved. The 2010 split-up of Fortune Brands is one example.

  • Moody's9 days ago

    Valeant Pharmaceuticals International, Inc -- Moody's assigns Caa1 to Valeant's unsecured notes; outlook stable

    Moody's Investors Service ("Moody's") assigned a Caa1 rating to the new senior unsecured note issuance of Valeant Pharmaceuticals International, guaranteed by Valeant Pharmaceuticals International, Inc. (collectively "Valeant"). There are no changes to Valeant's other ratings including the B3 Corporate Family Rating, the B3-PD Probability of Default Rating, the Ba3 senior secured rating, Caa1 senior unsecured rating and SGL-2 Speculative Grade Liquidity Rating.

  • Valeant Pharmaceuticals’ U.S. Diversified Products in 1Q18
    Market Realist9 days ago

    Valeant Pharmaceuticals’ U.S. Diversified Products in 1Q18

    In 1Q18, Valeant Pharmaceuticals’ (VRX) U.S. Diversified Products segment reported net revenues of $299.0 million compared to $346.0 million in 1Q17. This trend represents an ~14.0% decline on a year-over-year (or YoY) basis and an ~11.0% decline quarter-over-quarter. In 1Q18, Valeant Pharmaceuticals’ U.S. Diversified Products segment reported a gross profit and gross margin of $250.0 million and 84.0%, respectively, compared to $297.0 million and 86.0% in 1Q17.

  • MarketWatch9 days ago

    Valeant launches $750 million bond offering, increases planned Term B loan borrowing

    Valeant Pharmaceuticals International Inc. said Thursday it has launched a $750 million offering of senior unsecured notes due 2027 and increased the size of planned term loan borrowings. The company said ...

  • How Valeant’s Xifaxan and Other Branded Drugs Performed in 1Q18
    Market Realist10 days ago

    How Valeant’s Xifaxan and Other Branded Drugs Performed in 1Q18

    In 1Q18, Valeant Pharmaceutical’s (VRX) Branded Rx drug Xifaxan reported revenues of $275.0 million. Xifaxan is used in decreasing the risk of overt hepatic encephalopathy recurrence in adults. Xifaxan is also used for the treatment of adult individuals with irritable bowel syndrome with diarrhea.

  • Valeant Pharmaceuticals’ Ortho Dermatology Segment
    Market Realist10 days ago

    Valeant Pharmaceuticals’ Ortho Dermatology Segment

    In April, Valeant Pharmaceuticals’ (VRX) Ortho Dermatologics division published positive results in the Journal of the American Academy of Dermatology for the first time from its Phase 3 trial. This trial evaluated the safety and efficacy of Duobrii lotion for the treatment of individuals with plaque psoriasis.

  • How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18
    Market Realist10 days ago

    How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18

    In 1Q18, Valeant Pharmaceuticals (VRX) Branded Rx segment generated revenues of $593.0 million, compared to $629.0 million in 1Q17. This reflected ~6.0% growth on a year-over-year (or YoY) basis and an ~1.0% decline quarter-over-quarter.

  • Bloomberg11 days ago

    Valeant Ex-CEO Wasn't Swayed by Philidor Warning, Witness Says

    Valeant Pharmaceuticals International Inc.’s former leadership approved a $133 million investment in a mail-order pharmacy in 2014 even after being warned of a potentially corrupt relationship at the heart of the deal, an ex-official at the drug manufacturer testified. The option-purchase agreement with Philidor Rx Services LLC is at the center of the government’s fraud and money-laundering trial of former Valeant executive Gary Tanner and ex-Philidor Chief Executive Officer Andrew Davenport. Tanner, who managed Valeant’s relationship with Philidor, allegedly manipulated his employer into the deal in exchange for a $9.7 million kickback.

  • Moody's11 days ago

    Valeant Pharmaceuticals International, Inc -- Moody's assigns Ba3 to Valeant's new credit facilities; outlook stable

    Moody's Investors Service ("Moody's") assigned Ba3 ratings to the new senior secured term loan and revolving credit agreement of co-borrowers Valeant Pharmaceuticals International, Inc. and Valeant Pharmaceuticals International (collectively "Valeant"). There are no changes to Valeant's other ratings including the B3 Corporate Family Rating, the B3-PD Probability of Default Rating, the Ba3 senior secured rating, Caa1 senior unsecured rating and SGL-2 Speculative Grade Liquidity Rating. The transaction is credit positive because it will extend Valeant's debt maturities and modestly reduce total interest costs.

  • Barrons.com11 days ago

    Valeant: Turning Around or Just Spinning?

    Valeant Pharmaceuticals International (VRX) is higher today, helped by an upgrade from Mizuho Securities. Analyst Irina Koffler upgraded the shares to Buy from Neutral and raised her price target to $27 from $15, writing that the move comes after a drug-by-drug review that shows the company is "growing its key brands and has stabilized losses from older products," and there is also potential for upside from its pipeline. Koffler writes that Valeant's portfolio now looks "Mylan (MYL)-like," i.e.

  • An Overview of Bausch + Lomb’s Top Products in 1Q18
    Market Realist11 days ago

    An Overview of Bausch + Lomb’s Top Products in 1Q18

    In 1Q18, Soflens, a product from Valeant Pharmaceuticals’ (VRX) vision care subsidiary, Bausch + Lomb, generated revenues of $73.0 million compared to $69.0 million in 1Q17. This trend reflected ~6.0% growth on a year-over-year (or YoY) basis and an ~6.0% decline quarter-over-quarter. In the contact lens market, Bausch + Lomb faces competition from Johnson & Johnson (JNJ) and Novartis (NVS).

  • The Wall Street Journal11 days ago

    Stocks to Watch: Home Depot, Amazon, Symantec, Wynn, CBS, Viacom, Tesla, Ford, Micron, Valeant

    Among the companies with shares expected to trade actively in Tuesday's session are Home Depot, Amazon.com, Symantec, Wynn Resorts and CBS.

  • How Did Bausch + Lomb Perform in 1Q18?
    Market Realist11 days ago

    How Did Bausch + Lomb Perform in 1Q18?

    In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.

  • An Overview of Valeant Pharmaceuticals’ Performance in 1Q18
    Market Realist11 days ago

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    In 1Q18, Valeant Pharmaceuticals’ (VRX) revenues witnessed an ~5.0% decline to reach $2.0 billion. Valeant Pharmaceuticals had an operating loss and net loss of ~$2.3 billion and ~$2.7 billion, respectively, in 1Q18. To learn more about its 1Q18 financial data, please read How Valeant Pharmaceuticals Performed in 1Q18.

  • Bill Ackman’s Big Deals Don’t Look Better in Hindsight
    Bloomberg11 days ago

    Bill Ackman’s Big Deals Don’t Look Better in Hindsight

    A new book portrays an activist investor who let his ego get in the way of good judgment.

  • Ex-Valeant Official Says He Suspected Secret Financial Stake
    Bloomberg12 days ago

    Ex-Valeant Official Says He Suspected Secret Financial Stake

    A former Valeant Pharmaceuticals International Inc. executive told a jury how he became concerned that one of his senior directors had a secret financial interest in a mail-order pharmacy that did business with the drug company. Laizer Kornwasser, one the government’s star witnesses in the fraud and money-laundering trial of Gary Tanner and Andrew Davenport, the former head of Philidor Rx Services LLC, took the witness stand Monday in Manhattan federal court.